Portal de Periódicos da CAPES

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

2013; Elsevier BV; Volume: 123; Issue: 9 Linguagem: Inglês

10.1182/blood-2013-07-513937

1528-0020

Hagop M. Kantarjian, Jorge E. Cortés, Dong‐Wook Kim, H. Jean Khoury, Tim H. Brümmendorf, Kimmo Porkka, Giovanni Martinelli, Simon Durrant, Eric Leip, Virginia Kelly, Kathleen Turnbull, Nadine Besson, Carlo Gambacorti‐Passerini,

Acute Lymphoblastic Leukemia research

Key Points Bosutinib had manageable toxicity and acceptable tolerability, with adverse events distinct from that of other tyrosine kinase inhibitors. Adverse events were primarily characterized by early-onset gastrointestinal events that were low grade, transient, and manageable.